Axsome Therapeutics (AXSM) closed at $145.04 on October 23, 2026, down 7.1% from the previous close, on volume of 1,561,046 shares (30-day average 807,340).
Data as of October 23, 2026.
23-Oct-2026
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
Globe Newswire (Wed, 7-Oct 7:00 AM ET)
Globe Newswire (Mon, 21-Sep 7:00 AM ET)
Globe Newswire (Thu, 17-Sep 7:00 AM ET)
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 7:00 AM ET)
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
Globe Newswire (Mon, 31-Aug 7:00 AM ET)
Axsome’s 46% Revenue Surge Underscores Expanding CNS Franchise and Pipeline Momentum
Market Chameleon (Mon, 10-Aug 3:30 AM ET)
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Mon, 10-Aug 7:00 AM ET)
Market Chameleon (Mon, 4-May 4:36 AM ET)
Market Chameleon (Wed, 8-Apr 5:35 AM ET)
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Axsome Therapeutics trades on the NASDAQ stock market under the symbol AXSM.
As of October 23, 2026, AXSM stock price declined to $145.04 with 1,561,046 million shares trading.
AXSM has a beta of 0.55, meaning it tends to be less sensitive to market movements. AXSM has a correlation of 0.03 to the broad based SPY ETF.
AXSM has a market cap of $7.60 billion. This is considered a Mid Cap stock.
Last quarter Axsome Therapeutics reported $218 million in Revenue and -$.99 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.12.
In the last 3 years, AXSM traded as high as $260.19 and as low as $55.02.
The top ETF exchange traded funds that AXSM belongs to (by Net Assets): VTI, VB, VBK, VXF, FBT.
AXSM has underperformed the market in the last year with a price return of +14.2% while the SPY ETF gained +14.3%. AXSM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.9% and -13.8%, respectively, while the SPY returned +3.2% and -2.4%, respectively.
AXSM support price is $152.01 and resistance is $160.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXSM shares will trade within this expected range on the day.
